Vildagliptin-13C5,15N

Vildagliptin-13C5,15N (LAF237-13C5,15N; NVP-LAF 237-13C5,15N) is a 13C- and 15N-labeled Vildagliptin (HY-14291) . Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1][2].

Product Specifications

CAS Number

[1044741-01-6]

Product Name Alternative

LAF237-13C5,15N; NVP-LAF 237-13C5,15N

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Dipeptidyl Peptidase; Ferroptosis; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/vildagliptin-13c5-15n.html

Solubility

10 mM in DMSO

Smiles

O=C([15N]1[13C@@H]([13CH2][13CH2][13CH2]1)[13C]#N)CNC23CC4(CC(CC(C4)C3)C2)O

Molecular Formula

C12 13C5H25N2 15NO2

Molecular Weight

309.36

Precautions

H302, H315, H319, H335

References & Citations

[1]Villhauer EB, et al. 1-[[ (3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano- (S) -pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 Jun 19;46 (13) :2774-89.|[2]Wu YJ, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in associationwith its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015 Feb;64 (2) :226-35.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-246.